The 35th edition of EY’s Beyond Borders Biotechnology Report provides an in-depth look at the US and European biotechnology industry’s standing within a quickly evolving transaction and financing environment. Shifts in monetary policy and the removal of overhanging uncertainty from the US Presidential election have created the right environment for large pharmaceutical companies to deploy their firepower, while smaller biotechs are taking advantage of strong valuations as they continue to churn out innovations. Changing consumer expectations and increased drug pricing scrutiny are also driving companies to take a closer look at commercial models and the therapeutic areas that will drive investment over the next decade. This panel will explore all of these topics – and more.